journal article·2025-10-28Open access

Application of Graph Neural Networks to Model Stem Cell Donor–Recipient Compatibility in the Detection and Classification of Leukemia

Saeeda Meftah Salem Eltanashi, Ayça Kurnaz Türkben

Applied Sciences· Volume 15· Issue 21

Abstract

Stem cell transplants are a common treatment for leukemia, and close donor–recipient matching improves their success. Machine learning models like support vector machine (SVM), convolutional neural networks (CNNs), and recurrent neural networks (RNNs) can have difficulty handling the complexity of genomic and immune data, which then lowers the accuracy of clinical predictions. This study looks at using graph neural networks (GNNs) in a different way. This method combines data such as single-nucleotide polymorphisms (SNPs), human leukocyte antigen (HLA) typing, and clinical details to create a graph that shows the relationship between donor and recipient pairs. The framework uses graph attention networks (GATs) to focus on key compatibility traits and Dynamic GNNs (DGNNs) to monitor changes in the immune system and the disease’s progression. With data from the 1000 Genomes Project, the model correctly identified matches with 97.68% to 99.74% accuracy and classified them with 98.76% to 99.4% accuracy, outperforming standard machine learning models. The model uses SNP similarity and HLA mismatches to assess compatibility, which enhances its match prediction and compatibility explanation capabilities. The results suggest that GNNs offer a helpful and understandable way to model donor–recipient matching, potentially assisting in early leukemia detection and personalized stem cell transplant plans.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Digital Imaging for Blood Diseases · Acute Myeloid Leukemia Research · vaccines and immunoinformatics approaches

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Electrical and Computer Engineering, Altinbas University, Istanbul 34000, Turkey

References (46)

Show source-provided references
1. A case report of donor cell-derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation10.18632/oncotarget.28686 ↗
2. Sharma, S.K. (2023). Relapse Post Allogeneic Stem Cell Transplant. Basics of Hematopoietic Stem Cell Transplant, Springer.10.1007/978-981-19-5802-1_51 ↗
3. Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia10.1016/j.leukres.2024.107546 ↗
4. Efficacy and feasibility of Pharmacoscopy-guided treatment for acute myeloid leukemia patients that exhausted all registered therapeutic options10.3324/haematol.2023.283224 ↗
5. Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: Incidence, natural history and treatment response10.1111/bjh.12847 ↗
6. Donor Specific Antibody–Mediated Rejection in Allogeneic Hematopoietic Stem Cell Transplant Recipients
7. Donor Cell Leukemia: A Review10.1016/j.bbmt.2010.10.010 ↗
8. Donor cell leukemia/myelodysplastic syndrome after allogeneic stem cell transplantation: A rare phenomenon with more challenges for hematologists10.1080/16078454.2021.1966224 ↗
9. European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation10.1038/s41375-018-0218-6 ↗
10. Inflammatory reprogramming of the solid tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes10.1016/j.xcrm.2025.101989 ↗
11. Stem cell donors should be screened for CHIP10.1182/bloodadvances.2019000394 ↗
12. Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia10.1016/j.stemcr.2020.07.008 ↗
13. Comparison of two reduced intensity conditioning regimens: Flu-Bu2 versus RIC-TBF in allogeneic hematopoietic stem cell transplantation10.1080/10428194.2023.2281269 ↗
14. Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group10.1002/ajh.25810 ↗
15. A Phase II Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children and Adolescents with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation10.1016/S2666-6367(21)00273-6 ↗
16. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease10.1111/bjh.13352 ↗
17. Outcomes of Treosulfan Vs. Busulfan Based Conditioning Regimens in Adult Patients Undergoing Allogeneic HSCT: Real Life Data from a Single Center10.1182/blood-2023-189049 ↗
18. Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study10.1002/hon.2187 ↗
19. A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen10.1016/j.bbmt.2011.11.007 ↗
20. A2M-LEUK: Attention-augmented algorithm for blood cancer detection in children10.1007/s00521-023-08678-8 ↗
21. Comparison of melphalan- And busulfan-based myeloablative conditioning in children undergoing allogeneic transplantation for acute myeloid leukemia or myelodysplasia10.1111/petr.13672 ↗
22. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia10.1002/pbc.24922 ↗
23. Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia10.1002/pbc.27481 ↗
24. Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens10.1038/s41409-020-01201-w ↗
25. Rabbit anti-human T-lymphocyte globulin and hematopoietic transplantation10.18632/oncotarget.20878 ↗
26. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: A multicentre, randomised, open-label, phase 3 trial10.1016/S1470-2045(17)30417-5 ↗
27. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study10.1182/blood-2011-03-338707 ↗
28. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial10.1016/S1470-2045(14)70243-8 ↗
29. Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group10.1200/JCO.2008.17.6065 ↗
30. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: Prognostic relevance of early and late assessment10.1038/leu.2015.59 ↗
31. T-cell-based immunotherapy of acute myeloid leukemia: Current concepts and future developments10.1038/s41375-021-01253-x ↗
32. Opportunities for immunotherapy in childhood acute myeloid leukemia10.1182/hematology.2019000357 ↗
33. Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia10.1182/blood.2019000904 ↗
34. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia10.1038/s41375-019-0548-z ↗
35. CAR T cells for other pediatric non–B-cell hematologic malignancies10.1182/hematology.2020000134 ↗
36. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies10.1182/blood-2017-01-761320 ↗
37. A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies10.1182/blood-2015-02-629527 ↗
38. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia10.1182/blood-2018-10-882944 ↗
39. Base-edited CAR T cells for combinational therapy against T cell malignancies10.1038/s41375-021-01282-6 ↗
40. An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies10.1182/blood.V130.Suppl_1.844.844 ↗
41. Monitoring of Minimal Residual Disease After Allogeneic Stem Cell Transplantation in Relapsed Childhood ALL Allows the Identification of Impending Relapse-Results of the ALL BFM SCT 2003 Trial10.1182/blood.V122.21.1995.1995 ↗
42. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: Is there any room for intervention?10.1111/bjh.12639 ↗
43. Analysis of risk factors for relapse after allogeneic hematopoietic stem cell transplantation in acute leukemia10.1080/16078454.2025.2532915 ↗
44. Comparison of Support Vector Machine and Decision Tree Algorithm Performance with Undersampling Approach in Predicting Heart Disease Based on Lifestyle10.30871/jaic.v9i2.8941 ↗
45. Fan, Q., Qu, B., Teng, J., Hui, A., and Toe, T.T. (2023, January 26–29). Acute lymphoblastic leukemia Classification Based on Convolutional Neural Network. Proceedings of the 6th International Conference on Artificial Intelligence and Big Data (ICAIBD 2023), Chengdu, China.10.1109/ICAIBD57115.2023.10206402 ↗
46. Gokulkannan, K., Mohanaprakash, T.A., Sherin Beevi, L., and Vijayalakshmi, R. (2024). Leukemia Net: Integrating attention depth wise Separable network-aided stacked feature pooling with weighted recurrent neural network-based leukemia detection model. Biomed. Signal Process. Control, 96.10.1016/j.bspc.2024.106459 ↗